Management of IgE‑Mediated Penicillin Allergy When Broad‑Spectrum Antibiotics Are Required

Beta‑Lactam Alternatives

Carbapenems (meropenem, imipenem, ertapenem) may be given without prior skin testing to patients with documented IgE‑mediated penicillin allergy, providing the most comprehensive coverage of gram‑negative organisms (including Pseudomonas), anaerobes, and, when combined with vancomycin, MRSA and selected atypical pathogens. 1, 2
Cross‑reactivity between carbapenems and penicillins is low (0.87 % [95 % CI 0.32‑2.32 %]). 1, 3
In a prospective cohort of 211 patients with skin‑test‑confirmed penicillin allergy, every individual tolerated a carbapenem without any adverse reaction, supporting safety in this population. Evidence level: prospective cohort. 1, 3
The 2022 American Academy of Allergy practice parameters and the 2023 Dutch SWAB guidelines strongly recommend administering carbapenems without prior testing in IgE‑mediated penicillin allergy. Guideline strength: strong recommendation. 1, 2
Carbapenems should be avoided in patients with a history of severe delayed cutaneous reactions (e.g., Stevens‑Johnson syndrome, toxic epidermal necrolysis) or organ‑involved delayed reactions; allergy specialist consultation is required in these cases. 1, 3

Aztreonam exhibits zero cross‑reactivity with penicillins for both IgE‑ and T‑cell‑mediated reactions and can be administered without prior testing. 1, 4
The only contraindication is a confirmed ceftazidime allergy, because aztreonam shares an identical R1 side chain with ceftazidime. 1, 4
Aztreonam lacks activity against gram‑positive organisms (including MRSA) and anaerobes, making it unsuitable as monotherapy when broad‑spectrum coverage is required. 1, 4
Compared with piperacillin‑tazobactam or cefepime, aztreonam is less effective against gram‑negative pathogens and shows rising resistance rates. 1

Cephalosporins whose R1 side chains differ from the culprit penicillin have negligible cross‑reactivity (<1 %) and can be safely used in IgE‑mediated penicillin allergy. 2
Cefazolin, which possesses a unique side chain not shared with any currently marketed penicillin, may be administered regardless of reaction severity or timing. 2
Amino‑cephalosporins (e.g., cephalexin, cefaclor) share the same side chain as amoxicillin and demonstrate a cross‑reactivity rate of 16.45 % (95 % CI 11.07‑23.75 %); these agents should be avoided. 2
When a cephalosporin with a similar side chain is needed, the 2023 Dutch guidelines advise use only if the allergic reaction occurred >5 years ago and only in a controlled setting. Guideline strength: conditional recommendation. 2

A detailed allergy history—capturing reaction timing (<1 h for immediate/IgE‑mediated vs. >1 h for delayed), specific symptoms (urticaria, angioedema, anaphylaxis, hypotension), and the exact penicillin involved—is essential to determine whether carbapenems can be given without testing or whether specialist consultation is required. 1, 3

Avoid reflexively excluding all beta‑lactams; doing so leads to inferior antimicrobial choices and poorer clinical outcomes. 1
Do not assume uniform cross‑reactivity across all cephalosporins; risk is dictated by side‑chain structure rather than generation. 2
Do not use aztreonam as sole therapy for broad‑spectrum empiric coverage because it lacks gram‑positive and anaerobic activity. 1, 4
Do not order penicillin skin testing in acute settings when carbapenems can be safely administered immediately based on documented IgE‑mediated allergy. 1

Aztreonam can be used safely in individuals with penicillin allergy because monobactams have no cross‑reactivity with penicillins, even after severe immediate‑type reactions. Strong recommendation from the Dutch Working Party on Antibiotic Policy. 5
Carbapenems (e.g., meropenem, imipenem, ertapenem) are considered safe for patients with suspected immediate‑type penicillin allergy; cross‑reactivity with penicillins is estimated at < 1 %. Strong recommendation to administer carbapenems without prior allergy testing. 5

Macrolides (azithromycin, clarithromycin) have no structural relationship to penicillins, sulfonamides, or fluoroquinolones and are therefore safe in this allergy profile. 6
Aminoglycosides (gentamicin, tobramycin, amikacin) possess a completely different mechanism and structure, showing no cross‑reactivity with penicillin, sulfonamide, or fluoroquinolone allergies. 6
Metronidazole, an imidazole derivative, is structurally distinct from penicillins, sulfonamides, and fluoroquinolones, making it a safe option. 6

Cross‑reactivity between penicillins and cephalosporins is low (≈ 2 %). Cephalosporins that have dissimilar side chains (e.g., cefazolin) can be administered safely even in patients with immediate‑type penicillin allergy. 5

All fluoroquinolones should be avoided in patients with a confirmed fluoroquinolone allergy; intra‑class cross‑reactivity occurs in about 10 % of such individuals, and moxifloxacin carries the highest anaphylaxis risk. 6

Gram‑positive infections (e.g., skin/soft‑tissue, respiratory):
- First‑line: clindamycin (FDA‑approved for penicillin‑allergic patients).
- Alternatives: vancomycin, linezolid, or macrolides. (Alternative options are supported by guideline consensus, but primary evidence is from non‑Praxis sources.)
Gram‑negative infections (e.g., urinary, intra‑abdominal):
- First‑line: aztreonam. [Citation: 5]
- Alternatives: carbapenems or aminoglycosides. [Citation: 5]
Anaerobic coverage (e.g., intra‑abdominal, aspiration):
- First‑line: metronidazole. [Citation: 6]

Carbapenem monotherapy (meropenem or imipenem) provides the broadest coverage and is safe despite penicillin allergy. [Citation: 5]
Combination regimens (aztreonam + vancomycin or aztreonam + metronidazole) can be tailored to suspected pathogens while respecting the allergy profile. [Citations: 6, 5]

Obtain a detailed allergy history for each drug class, recording timing of reaction, specific symptoms (e.g., urticaria, anaphylaxis, rash), and whether the reaction was immediate (< 1 hour) or delayed (> 1 hour). This information guides assessment of IgE‑mediated versus T‑cell‑mediated mechanisms and informs future testing or treatment decisions. [Citation: 7]